Overview

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Status:
Completed

Trial end date:
2017-09-20

Target enrollment:

Participant gender:

Summary

This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD

Phase:

Phase 3

Details

Lead Sponsor:

Ohio State University

Collaborator:

Food and Drug Administration (FDA)

Treatments:

Cyclosporine
Cyclosporins
Prednisone